281 related articles for article (PubMed ID: 24580082)
21. Riociguat: a novel new drug for treatment of pulmonary hypertension.
Makowski CT; Rissmiller RW; Bullington WM
Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
[TBL] [Abstract][Full Text] [Related]
22. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
23. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
Ghofrani HA; D'Armini AM; Grimminger F; Hoeper MM; Jansa P; Kim NH; Mayer E; Simonneau G; Wilkins MR; Fritsch A; Neuser D; Weimann G; Wang C;
N Engl J Med; 2013 Jul; 369(4):319-29. PubMed ID: 23883377
[TBL] [Abstract][Full Text] [Related]
24. Riociguat for the treatment of pulmonary hypertension.
Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA
Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889
[TBL] [Abstract][Full Text] [Related]
25. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
Ghio S; Bonderman D; Felix SB; Ghofrani HA; Michelakis ED; Mitrovic V; Oudiz RJ; Frey R; Roessig L; Semigran MJ
Eur J Heart Fail; 2012 Aug; 14(8):946-53. PubMed ID: 22719060
[TBL] [Abstract][Full Text] [Related]
26. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Mielniczuk LM; Swiston JR; Mehta S
Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
[TBL] [Abstract][Full Text] [Related]
27. Unusual Bleeding Due to Riociguat Use in a Patient With Chronic Thromboembolic Pulmonary Hypertension.
Sonmez A; Sunbul M; Yildizeli B; Mutlu B
Am J Ther; 2016; 23(5):e1253-4. PubMed ID: 26270800
[TBL] [Abstract][Full Text] [Related]
28. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
[TBL] [Abstract][Full Text] [Related]
29. Clinically Worsening Chronic Thromboembolic Pulmonary Hypertension by Riociguat After Balloon Pulmonary Angioplasty.
Minatsuki S; Hatano M; Kiyosue A; Saito A; Maki H; Takimoto E; Komuro I
Int Heart J; 2018 Sep; 59(5):1186-1188. PubMed ID: 30158388
[TBL] [Abstract][Full Text] [Related]
30. Riociguat for the treatment of pulmonary hypertension: a safety evaluation.
Binder C; Zotter-Tufaro C; Bonderman D
Expert Opin Drug Saf; 2016 Dec; 15(12):1671-1677. PubMed ID: 27750459
[TBL] [Abstract][Full Text] [Related]
31. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
32. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F
Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034
[TBL] [Abstract][Full Text] [Related]
33. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
Hoeper MM; Halank M; Wilkens H; Günther A; Weimann G; Gebert I; Leuchte HH; Behr J
Eur Respir J; 2013 Apr; 41(4):853-60. PubMed ID: 22936711
[TBL] [Abstract][Full Text] [Related]
34. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Sharkovska Y; Kalk P; Lawrenz B; Godes M; Hoffmann LS; Wellkisch K; Geschka S; Relle K; Hocher B; Stasch JP
J Hypertens; 2010 Aug; 28(8):1666-75. PubMed ID: 20613628
[TBL] [Abstract][Full Text] [Related]
35. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
Evgenov OV; Ichinose F; Evgenov NV; Gnoth MJ; Falkowski GE; Chang Y; Bloch KD; Zapol WM
Circulation; 2004 Oct; 110(15):2253-9. PubMed ID: 15466650
[TBL] [Abstract][Full Text] [Related]
36. Riociguat for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Larche NE; Mousa SA
Drugs Today (Barc); 2013 Dec; 49(12):761-8. PubMed ID: 24524094
[TBL] [Abstract][Full Text] [Related]
37. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
[TBL] [Abstract][Full Text] [Related]
38. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.
Grimminger F; Weimann G; Frey R; Voswinckel R; Thamm M; Bölkow D; Weissmann N; Mück W; Unger S; Wensing G; Schermuly RT; Ghofrani HA
Eur Respir J; 2009 Apr; 33(4):785-92. PubMed ID: 19129292
[TBL] [Abstract][Full Text] [Related]
39. Animal models related to congenital heart disease and clinical research in pulmonary hypertension.
Loukanov T; Geiger R; Agrawal R
Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
Ying M; Song J; Gu S; Zhao R; Li M
Medicine (Baltimore); 2021 Jun; 100(22):e26211. PubMed ID: 34087896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]